Direct and indirect antitumor activity of zoledronic acid


https://doi.org/10.4081/hmr.v1i8.294
Vol. 1 No. 8: New Drugs in Hematology, Bologna, October 9-11, 2005
Published: June 3, 2009
Abstract Views: 210
PDF: 275
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Zoledronic acid (Zol) is the most potent aminobisphosphonate currently available to treat bone disease in cancer patients.1 Zol specifically targets the mevalonate (MVA) pathway of osteclasts precursors and mature osteoclasts. By inhibiting the farnesyl pyrophosphate (FPP) synthase, Zol prevents the generation of FPP and geranylgeranylpyrophosphate (GGPP) that are essential compounds to prenylate proteins like Ras and Rho among others.2 The accumulation of unprenylated proteins in osteoclast precursors and mature osteclasts prevents their differentiation and activation and ultimately leads to cell death by apoptosis. By acting upstream on the same pathway targeted by farnesyl transferase (FTase) and geranylgeranyltransferase (GGTase) inhibitors (FTI, GGTI), Zol can be considered as a drug impacting on farnesylation-dependent survival and differentiation pathways.

Supporting Agencies


Massaia, M., Mariani, S., Pantaleoni, F., Muraro, M., Peola, S., Hwang, S., Castella, B., & Matta, G. (2009). Direct and indirect antitumor activity of zoledronic acid. Hematology Meeting Reports (formerly Haematologica Reports), 1(8). https://doi.org/10.4081/hmr.v1i8.294
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC